IDCRC Newsletter: April 2026

IDCRC Spotlight: Marcela F. Pasetti, PhD, Endpoint Laboratory Principal Investigator, University of Maryland School of Medicine

This month's IDCRC investigator spotlight features Marcela F. Pasetti, PhD, the Endpoint Laboratory principal investigator for the PROMISE and Measles study at the University of Maryland School of Medicine. Dr. Pasetti is an immunologist, professor of pediatrics, and also serves as the chief of the Applied Immunology Section at the Center for Vaccine Development.

"The IDCRC is unique in its capacity to advance clinical research. It supports high-complexity, rigorous clinical trials involving multiple sites. It brings together accomplished investigators of multiple disciplines and institutions."

Annual Meeting

2026 IDCRC Annual Meeting is two weeks away!

The 2026 Annual Meeting is just two weeks away! We look forward to seeing many of our Leadership Group, VTEU members, and DMID colleagues for our two-day meeting. This year's robust program will highlight the numerous scientific accomplishments of the IDCRC and VTEUs and provide ample networking opportunities for members. 

Meeting Overview:

• Date: May 13-May 14
• Location: NIAID Building, 5601 Fishers Lane, Rockville, MD, 20892
• Visit the Annual Meeting webpage for information, including meeting goals, draft agenda, accommodations, and local dining options.

Reminder: This will be an invitation-only meeting for members of the IDCRC (VTEU and LG) and DMID. All attendees (in person and virtual) must have registered to attend. Virtual attendees will receive the meeting login information prior to the meeting with the email address provided at registration. 

Questions? Contact idcrc@emory.edu for more information.

Annual Meeting Schedule of Events

Help us capture this year's meeting!

Publications

NOTE: Please include the following citation in any publications resulting from direct or indirect IDCRC support: 

"Supported by the Infectious Diseases Clinical Research Consortium through the National Institute for Allergy and Infectious Diseases of the National Institutes of Health, under award number UM1AI148684. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health."

View recent publications and updated quick stats below:

Training

IDCRC Mentee Profile: Lauren Jatt, MD

I am most looking forward to the opportunity to learn from and interact with leading vaccinologists through the IDCRC Mentorship Program. I am also excited to build lasting relationships with my cohort, developing a sense of camaraderie and a professional network that will serve as a source of collaboration, support, and shared learning throughout our careers.

News

NFID| There’s Nothing New About Applying a ‘Gold Standard’ to Vaccine Trials with Angela Branch, MD

So let me, a vaccinologist who has participated in many clinical trials, shed some light on this issue. Vaccine trial design begins with understanding the disease. Clinician-scientists who treat patients and study epidemiology help identify who needs protection and why, and often lead trial design, working with the National Institutes of Health, Centers for Disease Control and Prevention (CDC), and industry partners to ensure that the best science is being done to develop vaccines that protect those most at risk.

IDSA | Let's Talk ID with Buddy Creech, MD, MPH, FPIDS

The American Association for the Advancement of Science
(AAAS) announces 2025 Fellows

AAAS selects Fellows for their outstanding efforts in the advancement of science based on research, teaching, administration, and technology, as well as communicating and interpreting science to the public. Becoming an AAAS Fellow is considered a lifetime honor. In addition to advancing research, Fellows play a crucial role in shaping public policy and influencing national and global perspectives on critical issues.

Job Postings

Newly Posted! Infectious Diseases Research Job Openings

• Center for Anti-Infective Research and Development (CAIRD), Hartford Hospital - Antimicrobial Research and Infectious Diseases Fellowship
• Centers for Disease Control and Prevention - Biologist
• Great Hill Solutions, LLC/Seneca Nation Group (SNG) - Epidemiologist III
• Virginia Commonwealth University  - Open Rank Faculty - Infectious Disease Epidemiology
• Washington University in St. Louis - Staff Scientist - Infectious Diseases

Visit the IDSA Career Center to browse other ID job postings.

Events

Harvard Medical School: Infectious Diseases in Adults 2026

Infectious Diseases in Adults 2026 provides state-of-the-art approaches for the prevention, diagnosis, and management of infectious diseases: common, challenging, rare, and emerging. Hear directly from world-renowned specialists and master clinicians on state-of-the-art methods to diagnose, treat, and prevent infectious diseases. This program comprehensively covers best practices for common, emerging, rare, and the most challenging diseases. 

Infectious Disease Board Review Course

This course is designed to help physicians prepare for the American Board of Internal Medicine (ABIM) Infectious Disease certification and recertification exams. This comprehensive program includes web access to the entire archived course plus primers and study guides, online-only lectures, photo-based questions, and over 500 ABIM-style questions.

Funding Opportunities

IDCRC Studies

Fully Enrolled Studies in Follow-up

• A Randomized, Double-Blind, Placebo-Controlled Phase 1 Trial to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of Sanaria(R) PfSPZ-LARC2 Vaccine, a Late-Arresting, Replication-Competent, Genetically Attenuated Plasmodium Falciparum Vaccine by Controlled Human Malaria Infection in Malaria-Naïve Healthy Adults Conditions (DMID 23-0010)
• Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults (DMID 23-0006)

• A Phase 1 Trial to Evaluate the Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine, HydroVax-001B WNV in Healthy Adults (DMID 24-0008)

• A Prospective, Randomized, Open-label Phase 4 Study of the Immunology and Safety of Maternal RSV Vaccination (ABRYSVOTM), Infant Nirsevimab (BEYFORTUSTM) Immunization, or Both Products During the First Year of Life (PROMISE) (DMID 24-0003)

IDCRC Concept Quick Stats

Communication Resources

Please submit IDCRC news to idcrc@emory.edu for inclusion in the monthly newsletter and IDCRC.org.